EAACI Biologicals Guidelines-Recommendations for severe asthma

Ioana Agache, Cezmi A Akdis, Mubeccel Akdis, Giorgio Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Derek K Chu, Stefano Del Giacco, Thomas Eiwegger, Breda Flood, Davide Firinu, James E Gern, Eckard Hamelmann, Nicola Hanania, Irene Hernández-Martín, Rebeca Knibb, Mika Mäkelä, Parameswaran Nair, Liam O'MahonyNikolaos G Papadopoulos, Alberto Papi, Hae-Sim Park, Luis Pérez de Llano, Oliver Pfaar, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Oscar Palomares, Marek Jutel

Research output: Journal article (peer-reviewed)Journal article

168 Citations (Scopus)


Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.

Original languageEnglish
Pages (from-to)14-44
Number of pages31
JournalAllergy: European Journal of Allergy and Clinical Immunology
Issue number1
Publication statusPublished - Jan 2021
Externally publishedYes


  • Asthma/diagnosis
  • Cost-Benefit Analysis
  • Humans
  • Phenotype


Dive into the research topics of 'EAACI Biologicals Guidelines-Recommendations for severe asthma'. Together they form a unique fingerprint.

Cite this